LIN-31 Inhibitors
Chemical inhibitors of LIN-31 can modulate the activity of this transcription factor through various mechanisms associated with cell signaling pathways. Palbociclib, a CDK4/6 inhibitor, can arrest the cell cycle in the G1 phase, which in turn can affect LIN-31, whose activity is intertwined with cell cycle progression. Similarly, Trametinib and U0126, both MEK inhibitors, and PD98059, a MEK1/2 inhibitor, can disrupt the MAPK/ERK pathway, leading to a decrease in LIN-31 functionality by preventing the necessary phosphorylation events that activate this transcription factor. Moreover, Rapamycin, an mTOR inhibitor, and AZD8055, which inhibits both mTORC1 and mTORC2 complexes, can lead to the downregulation of LIN-31 activity by interfering with mTOR signaling involved in cell growth and proliferation, processes where LIN-31 is also implicated.
Furthermore, LY294002 and Wortmannin, PI3K inhibitors, can lead to a decrease in LIN-31 activity by blocking the PI3K/Akt pathway, which is potentially involved in the regulation of LIN-31. SB203580 and SP600125, inhibitors of p38 MAPK and JNK respectively, can decrease LIN-31 activity by preventing the activation of pathways that might contribute to its function. Additionally, Y-27632, a ROCK inhibitor, can affect cell dynamics that involve LIN-31, leading to alterations in its activity within the contexts of cell shape and motility. Lastly, SL0101, an inhibitor of the p90 ribosomal S6 kinase (RSK), can impair the downstream signaling of the ERK pathway, which can lead to reduced activity of LIN-31, further demonstrating the diverse mechanisms through which these chemical inhibitors can modulate the function of this transcription factor.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor that can halt the cell cycle in the G1 phase. LIN-31 is a transcription factor that is active during the cell cycle; by inhibiting CDK4/6, Palbociclib indirectly inhibits the progression of the cell cycle and thus the activity of LIN-31, which relies on proper cell cycle progression to perform its function. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor that prevents the activation of the MAPK/ERK pathway. The MAPK/ERK pathway is involved in regulating the activity of transcription factors, including LIN-31. By inhibiting MEK, Trametinib suppresses the MAPK/ERK signaling, which is necessary for LIN-31 to regulate its target genes involved in cell differentiation and proliferation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor which disrupts the mTOR signaling pathway. As the mTOR pathway is involved in cell growth and proliferation, which are processes where LIN-31 is also involved, inhibiting mTOR with Rapamycin can indirectly lead to a decrease in LIN-31 activity due to the disruption of these cellular processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/Akt signaling pathway. This pathway can regulate transcription factor activity, and LIN-31 activity could be contingent on signals transduced through this pathway. Inhibiting PI3K can thus lead to reduced LIN-31 activity as it disrupts the signaling required for its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, which is part of the MAPK/ERK pathway, a pathway that can regulate the activity of various transcription factors, including LIN-31. By inhibiting this pathway, U0126 can lead to decreased LIN-31 function by blocking the necessary signals for its activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. The p38 MAPK pathway can influence the activity of different transcription factors. Inhibition of p38 MAPK by SB203580 can lead to decreased LIN-31 activity by preventing the activation of pathways that contribute to its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathways. JNK pathway can modulate transcription factors' activity, including LIN-31. Inhibition of JNK by SP600125 can decrease LIN-31 activity through disruption of signaling required for LIN-31 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that prevents activation of the PI3K/Akt pathway. Since LIN-31 can be regulated by signaling cascades involving PI3K, inhibiting this kinase with Wortmannin can lead to decreased LIN-31 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK1/2, which are upstream regulators of the MAPK/ERK pathway. By inhibiting MEK1/2, PD98059 can disrupt the signaling required for LIN-31 activity, leading to its functional inhibition. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor that can affect cell shape and motility, which are processes that may involve LIN-31. By inhibiting ROCK, Y-27632 may lead to altered cell dynamics and potentially decrease the functional activity of LIN-31 within these contexts. | ||||||